Genmab A/S (NASDAQ:GMAB) Downgraded by Zacks Research to Hold

Zacks Research cut shares of Genmab A/S (NASDAQ:GMAB) from a strong-buy rating to a hold rating in a research note released on Tuesday morning,Zacks.com reports.

Several other brokerages also recently weighed in on GMAB. HC Wainwright increased their price target on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Friday, August 15th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research note on Monday, July 28th. Finally, Truist Financial boosted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.60.

Genmab A/S Price Performance

Shares of GMAB opened at $24.06 on Tuesday. The company’s fifty day moving average price is $21.87 and its 200-day moving average price is $21.00. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $27.94. The firm has a market capitalization of $15.44 billion, a PE ratio of 12.09, a price-to-earnings-growth ratio of 6.91 and a beta of 0.95.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GMAB. Headlands Technologies LLC boosted its stake in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after acquiring an additional 1,464 shares in the last quarter. CWM LLC boosted its position in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after purchasing an additional 1,070 shares during the period. AlphaCore Capital LLC purchased a new stake in shares of Genmab A/S in the second quarter valued at approximately $44,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after buying an additional 1,174 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.